23-valent Pneumococcal Vaccine Market was valued at USD 2.5 Billion in 2022 and is projected to reach USD 4.0 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030.
The 23-valent Pneumococcal Vaccine (PPSV23) is designed to protect against 23 strains of the Streptococcus pneumoniae bacteria, which is responsible for a range of severe infections including pneumonia, meningitis, and sepsis. The market for this vaccine has witnessed significant growth due to rising awareness about pneumococcal diseases and their severe complications, particularly among vulnerable populations. The vaccine is administered to prevent infections in individuals who are at high risk due to underlying health conditions, such as chronic cardiovascular diseases, chronic lung diseases, or compromised immune systems. The demand for PPSV23 is projected to increase, driven by healthcare providers' emphasis on preventative measures and the rising prevalence of these health conditions globally. As global healthcare systems aim to enhance vaccination coverage, the 23-valent pneumococcal vaccine is poised to remain a crucial element in managing public health.
Download Full PDF Sample Copy of Global 23-valent Pneumococcal Vaccine Report @ https://www.verifiedmarketreports.com/download-sample/?rid=898520&utm_source=Google_site&utm_medium=231
The 23-valent Pneumococcal Vaccine market is segmented by various applications, as its use is particularly vital for individuals with certain chronic conditions. This market primarily revolves around high-risk populations who are more susceptible to severe pneumococcal infections. The applications span a wide range of chronic conditions, from cardiovascular diseases to immune system deficiencies. The vaccine's primary role in these applications is to reduce the incidence of pneumococcal infections, which could lead to severe complications or even death if left untreated. As public health awareness about chronic diseases rises, healthcare professionals are increasingly emphasizing vaccination as a preventative tool. This is expected to drive the market forward as demand for the vaccine among vulnerable populations grows.
Chronic cardiovascular diseases (CVD) are among the leading causes of death worldwide, and individuals suffering from CVD are at a heightened risk of infections, including pneumococcal disease. The 23-valent pneumococcal vaccine plays a critical role in reducing the risk of pneumonia and other infections in CVD patients, who may have weakened immune responses due to their condition or its treatment. Patients with chronic cardiovascular conditions are more vulnerable to complications from pneumococcal infections, which can significantly affect their health outcomes. The growing prevalence of CVD globally has created a larger market for the PPSV23 vaccine, as it becomes an essential part of routine preventative care in cardiovascular disease management.
The vaccination against pneumococcal diseases in CVD patients is particularly important because these individuals often experience prolonged hospital stays and a higher risk of complications from infections. In addition to the direct benefits of preventing pneumococcal infections, vaccination in CVD patients can reduce healthcare costs by avoiding the need for more expensive treatments related to infections. As the number of cardiovascular disease cases rises, particularly among aging populations, the market for the 23-valent pneumococcal vaccine is expected to continue expanding, with healthcare providers prioritizing vaccination in their care protocols for CVD patients.
Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, are prevalent conditions that significantly affect individuals' respiratory systems, making them more susceptible to infections like pneumonia. Pneumococcal infections can exacerbate these conditions, leading to severe respiratory complications and hospitalizations. The 23-valent pneumococcal vaccine is particularly beneficial for individuals suffering from chronic lung diseases, as it helps reduce the risk of pneumococcal pneumonia, one of the most common respiratory infections. As these diseases are widespread and chronic, there is a significant demand for PPSV23 in the market, as healthcare professionals recognize the need for vaccination as part of comprehensive disease management strategies.
Vaccinating individuals with chronic lung diseases against pneumococcal infection is crucial to prevent exacerbations that can worsen lung function and lead to frequent hospitalizations. In COPD and other chronic lung disease patients, pneumococcal infections can lead to acute respiratory distress and even respiratory failure, significantly impacting the quality of life. As the prevalence of chronic lung diseases continues to rise globally, particularly in aging populations and regions with high smoking rates, the demand for the 23-valent pneumococcal vaccine is expected to increase. This growing need presents substantial opportunities for vaccine manufacturers to expand their presence in the chronic respiratory disease segment.
Individuals suffering from chronic liver disease are more vulnerable to infections due to their compromised immune systems. Chronic liver diseases, including cirrhosis and hepatitis, can severely impair the body's ability to fight infections, making pneumococcal infections particularly dangerous. The 23-valent pneumococcal vaccine is a key preventive tool in this patient group, reducing the risk of pneumococcal pneumonia, which can lead to severe health complications. As liver disease rates increase, especially in regions with high alcohol consumption or hepatitis prevalence, the market for PPSV23 is expected to see a rise. Healthcare providers are increasingly recommending the vaccine as part of standard care for individuals with chronic liver conditions.
Chronic liver disease patients often have additional health complications and may experience more severe outcomes when infected with pneumococcal bacteria. The vaccine helps protect against these risks, which can lead to unnecessary hospital admissions and long-term health complications. With the growing awareness of chronic liver disease and the increasing emphasis on preventative care, the demand for pneumococcal vaccination in this market segment is expected to grow. This creates new opportunities for healthcare providers to offer vaccinations as part of routine care for liver disease patients, especially in high-risk populations.
People living with HIV have weakened immune systems, making them highly susceptible to infections such as pneumonia, which is often caused by pneumococcal bacteria. The 23-valent pneumococcal vaccine is essential in protecting HIV patients, as it helps reduce the risk of severe pneumococcal infections that could lead to additional complications. The increasing global prevalence of HIV, particularly in regions with limited access to healthcare, has driven the demand for pneumococcal vaccines in this population. Vaccination is a key preventive measure for individuals living with HIV, as it offers an effective means to reduce the burden of pneumococcal diseases.
For people living with HIV, pneumococcal infections can significantly impair their overall health, potentially accelerating the progression of HIV and leading to serious complications such as pneumonia or sepsis. The 23-valent vaccine is a key component of the care regimen for HIV patients, helping to reduce the occurrence of these infections. With global efforts to improve HIV care and prevention, the market for pneumococcal vaccines in this demographic is expected to grow. As access to healthcare improves, vaccination rates are likely to rise, further boosting demand for PPSV23 in HIV-positive populations.
Leukemia patients often undergo treatments that suppress their immune systems, making them more vulnerable to infections, including those caused by pneumococcal bacteria. The 23-valent pneumococcal vaccine is crucial in protecting these patients from pneumococcal pneumonia, which could further compromise their already weakened immune systems. As the incidence of leukemia rises globally, the demand for PPSV23 is likely to increase. Vaccination serves as an essential part of leukemia care protocols, providing an added layer of protection against respiratory infections that can complicate treatment outcomes.
Pneumococcal infections in leukemia patients can lead to severe complications, including prolonged hospitalizations, additional treatments, and increased mortality risks. As such, vaccination is an integral part of preventive healthcare for leukemia patients, reducing the risks associated with pneumococcal diseases. With growing awareness of the importance of immunization for cancer patients and the increasing prevalence of leukemia, the market for pneumococcal vaccines in this segment is expected to expand significantly.
Lymphoma patients, like those with leukemia, often undergo treatments that compromise their immune systems, making them particularly susceptible to infections such as pneumococcal disease. The 23-valent pneumococcal vaccine is a key preventive measure to protect lymphoma patients from severe pneumococcal infections, which can significantly impact their recovery and treatment outcomes. As the incidence of lymphoma increases, so too does the demand for PPSV23, with healthcare providers increasingly recognizing the importance of vaccinating patients with compromised immunity to prevent complications related to pneumococcal infections.
Given the high risk of infections during and after lymphoma treatment, vaccination with the 23-valent pneumococcal vaccine offers essential protection against severe diseases like pneumonia, which can cause additional morbidity and mortality. The growing awareness of the need for vaccination in immunocompromised patients is expected to drive the demand for PPSV23 in lymphoma patients. The increasing focus on comprehensive cancer care and patient well-being further supports the expansion of the pneumococcal vaccine market in this area.
Multiple myeloma, a cancer of the plasma cells in the bone marrow, weakens the immune system, making patients highly vulnerable to infections, including pneumococcal diseases. The 23-valent pneumococcal vaccine is an important preventive measure for these patients, helping to protect them from pneumococcal infections that can complicate their treatment and recovery. As the prevalence of multiple myeloma increases globally, particularly among aging populations, the market for PPSV23 in this segment is expected to grow. Healthcare providers are increasingly focusing on vaccination to reduce infection risks and improve the quality of care for myeloma patients.
Multiple myeloma patients are often at high risk for respiratory infections, which can lead to complications such as pneumonia or sepsis. Pneumococcal
Download Full PDF Sample Copy of Global 23-valent Pneumococcal Vaccine Report @ https://www.verifiedmarketreports.com/download-sample/?rid=898520&utm_source=Google_site&utm_medium=231
Merck
Sanofipasteur
CDIBP
Kexing Bio
Changsheng Bio-Technology
Huaan Science and Technology Innovation
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase Of This Report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=898520&utm_source=Google_site&utm_medium=231
Growing demand for below applications around the world has had a direct impact on the growth of the Global 23-valent Pneumococcal Vaccine Market
Chronic Cardiovascular Disease
Chronic Lung Disease
Chronic Liver Disease
People Living with Hiv
Leukemia
Lymphoma
Multiple Myeloma
General Malignancy
Chronic Kidney Disease
Other
Based on Types the Market is categorized into Below types that held the largest 23-valent Pneumococcal Vaccine market share In 2023.
Single Dose Vial
Pre-filled Syringe
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ https://www.verifiedmarketreports.com/product/23-valent-pneumococcal-vaccine-market/
1. Introduction of the Global 23-valent Pneumococcal Vaccine Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global 23-valent Pneumococcal Vaccine Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global 23-valent Pneumococcal Vaccine Market, By Type
6. Global 23-valent Pneumococcal Vaccine Market, By Application
7. Global 23-valent Pneumococcal Vaccine Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global 23-valent Pneumococcal Vaccine Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/